Cascinu S, Valentini G, Catalano G
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy.
Tumori. 1993 Oct 31;79(5):331-5. doi: 10.1177/030089169307900509.
The study was performed to assess the toxicity and impact on relapse pattern of postoperative intraperitoneal cisplatin, 5-fluorouracil, leucovorin and interferon therapy as adjuvant treatment for gastric cancer patients who are at high risk for recurrence after potentially curative resection (T2 N1-2; T3-4 N any Mo).
Starting 14 to 21 days after potentially curative resection of primary gastric cancers, 22 patients were given intraperitoneal cisplatin, 60 mg/m2; 5-fluorouracil, 1000 mg/m2; 6S-leucovorin, 250 mg/m2; interferon alpha 2b, 10 MU/m2; every other week for six times.
After a median follow-up of 24 months, 63% of patients were alive and free of disease. Eight patients had recurred; five had an intraabdominal component, and 3 had extraabdominal failure. Toxicity was mild: no grade III-IV WHO toxicity was observed.
Intraperitoneal cisplatin, 5-fluorouracil, 6S-leucovorin and interferon is a tolerable therapy in the postoperative setting for patients with resected gastric cancer. These data make this approach interesting for the development of new programs of adjuvant therapy of high-risk gastric cancer.
本研究旨在评估术后腹腔内使用顺铂、5-氟尿嘧啶、亚叶酸钙和干扰素治疗对胃癌患者的毒性作用以及对复发模式的影响，这些患者在接受潜在根治性切除术后复发风险较高（T2 N1-2；T3-4 N 任何 Mo）。
在原发性胃癌潜在根治性切除术后14至21天开始，22例患者接受腹腔内注射顺铂，60 mg/m²；5-氟尿嘧啶，1000 mg/m²；6S-亚叶酸钙，250 mg/m²；干扰素α2b，10 MU/m²；每两周一次，共六次。
中位随访24个月后，63%的患者存活且无疾病。8例患者复发；5例有腹腔内复发，3例有腹腔外复发。毒性反应轻微：未观察到世界卫生组织（WHO）III-IV级毒性反应。
对于接受胃癌切除术的患者，术后腹腔内使用顺铂、5-氟尿嘧啶、6S-亚叶酸钙和干扰素是一种可耐受的治疗方法。这些数据使得这种方法对于高危胃癌辅助治疗新方案的开发具有吸引力。
